JP2000063242A - Hair tonic - Google Patents
Hair tonicInfo
- Publication number
- JP2000063242A JP2000063242A JP10247774A JP24777498A JP2000063242A JP 2000063242 A JP2000063242 A JP 2000063242A JP 10247774 A JP10247774 A JP 10247774A JP 24777498 A JP24777498 A JP 24777498A JP 2000063242 A JP2000063242 A JP 2000063242A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- acid
- growth
- medium
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 66
- 230000001256 tonic effect Effects 0.000 title abstract description 7
- 235000000346 sugar Nutrition 0.000 claims abstract description 36
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 150000004671 saturated fatty acids Chemical group 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- 229930182830 galactose Natural products 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 229930091371 Fructose Natural products 0.000 claims abstract description 5
- 239000005715 Fructose Substances 0.000 claims abstract description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 5
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims description 22
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 15
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 8
- 235000020778 linoleic acid Nutrition 0.000 claims description 8
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 claims description 4
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 claims description 4
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000003779 hair growth Effects 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 49
- 230000031774 hair cycle Effects 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 9
- 239000007788 liquid Substances 0.000 abstract description 8
- 238000009472 formulation Methods 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract description 4
- 239000004909 Moisturizer Substances 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- 230000001333 moisturizer Effects 0.000 abstract description 3
- 239000004094 surface-active agent Substances 0.000 abstract description 3
- 239000002562 thickening agent Substances 0.000 abstract description 3
- 235000017788 Cydonia oblonga Nutrition 0.000 abstract description 2
- 229960003966 nicotinamide Drugs 0.000 abstract description 2
- 235000005152 nicotinamide Nutrition 0.000 abstract description 2
- 239000011570 nicotinamide Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004889 salicylic acid Drugs 0.000 abstract description 2
- 239000002453 shampoo Substances 0.000 abstract description 2
- 229940124549 vasodilator Drugs 0.000 abstract description 2
- 239000003071 vasodilator agent Substances 0.000 abstract description 2
- 241000282994 Cervidae Species 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 210000003780 hair follicle Anatomy 0.000 description 64
- 239000002609 medium Substances 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 41
- 239000003795 chemical substances by application Substances 0.000 description 35
- 210000002919 epithelial cell Anatomy 0.000 description 30
- 239000013076 target substance Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000003698 anagen phase Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 210000004919 hair shaft Anatomy 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- -1 rinse Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 229940122618 Trypsin inhibitor Drugs 0.000 description 5
- 101710162629 Trypsin inhibitor Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003255 drug test Methods 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 239000002753 trypsin inhibitor Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000008556 epithelial cell proliferation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 125000005471 saturated fatty acid group Chemical group 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical compound CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940060296 dodecylbenzenesulfonic acid Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- VXZBFBRLRNDJCS-UHFFFAOYSA-N heptacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VXZBFBRLRNDJCS-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- WBBQTNCISCKUMU-PDBXOOCHSA-N (13Z,16Z,19Z)-docosatrienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCCCC(O)=O WBBQTNCISCKUMU-PDBXOOCHSA-N 0.000 description 1
- GEHPRJRWZDWFBJ-FOCLMDBBSA-N (2E)-2-heptadecenoic acid Chemical compound CCCCCCCCCCCCCC\C=C\C(O)=O GEHPRJRWZDWFBJ-FOCLMDBBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- ZJVATSUMFCZSKA-QZOPMXJLSA-N (z)-docos-13-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O ZJVATSUMFCZSKA-QZOPMXJLSA-N 0.000 description 1
- JYDNQSLNPKOEII-BZSWNNBUSA-N (z)-hexadec-9-enoic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O.CCCCCC\C=C/CCCCCCCC(O)=O JYDNQSLNPKOEII-BZSWNNBUSA-N 0.000 description 1
- PEPLYFKDJRTLKB-KBFCSHFYSA-N (z)-octadec-6-enoic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O.CCCCCCCCCCC\C=C/CCCCC(O)=O PEPLYFKDJRTLKB-KBFCSHFYSA-N 0.000 description 1
- DHEMVUXAYZGHFQ-QZOPMXJLSA-N (z)-tetracos-15-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O DHEMVUXAYZGHFQ-QZOPMXJLSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- GQVYBECSNBLQJV-VAWYXSNFSA-N 3-n-decyl acrylic acid Chemical compound CCCCCCCCCC\C=C\C(O)=O GQVYBECSNBLQJV-VAWYXSNFSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- GZZPOFFXKUVNSW-UHFFFAOYSA-N Dodecenoic acid Natural products OC(=O)CCCCCCCCCC=C GZZPOFFXKUVNSW-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940096898 glyceryl palmitate Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002488 outer root sheath cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- XXHDAWYDNSXJQM-ONEGZZNKSA-N trans-hex-3-enoic acid Chemical compound CC\C=C\CC(O)=O XXHDAWYDNSXJQM-ONEGZZNKSA-N 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、育毛剤に関する技
術分野に属する発明である。より詳細には、毛髪伸長の
促進をすることによって毛周期における成長期を維持又
は延長する毛髪成長期延長効果を有する育毛剤に関す
る。TECHNICAL FIELD The present invention belongs to the technical field relating to hair-growth agents. More specifically, it relates to a hair-growth agent having a hair-growth-prolonging effect of maintaining or prolonging the growth phase in the hair cycle by promoting hair growth.
【0002】[0002]
【従来の技術】高齢化社会、ストレス社会といわれる現
代社会では、頭部毛髪が様々な原因により脱毛の危機に
さらされる機会がますます多くなってきている。これに
対応して、より優れた「育毛剤」を提供すべく様々な試
みがなされている。育毛剤が毛髪に与える効果として主
なものに、発毛誘導効果(発毛促進効果,成長期誘導
効果),毛髪を太くする効果,毛髪成長期延長効
果,5α−レダクターゼ阻害効果,血行促進効果,
殺菌効果,フケ防止効果,保湿効果,抗酸化効
果等の効果が挙げられる。2. Description of the Related Art In modern society, which is said to be an aging society and a stress society, head hair is increasingly exposed to hair loss due to various causes. In response to this, various attempts have been made to provide a superior “hair growth agent”. The main effects of hair restorers on hair are: hair growth inducing effect (hair growth promoting effect, growth phase inducing effect), hair thickening effect, hair growth phase extending effect, 5α-reductase inhibitory effect, blood circulation promoting effect. ,
It has effects such as bactericidal effect, anti-dandruff effect, moisturizing effect, and antioxidant effect.
【0003】しかしながら、前記のように種々の試みが
なされているにもかかわらず、従来の育毛剤では、その
脱毛防止,発毛効果等の育毛作用は必ずしも十分なもの
ではなかった。これはおそらく脱毛の原因がさまざまで
あり、また発毛の機構も非常に複雑であるためと考えら
れている。今まで提供されている「育毛剤」は、脱毛を
比較的大雑把な概念、言い換えれば漫然と「脱毛」とい
う現象のみを捉えて開発されており、そのメカニズムに
まで突っ込んで着目して開発されたものは決して多くな
い。その大きな理由が、これらのメカニズムに着目した
育毛効果を簡便に検定することが可能な育毛薬剤検定方
法が十分に提供されていなかったという面を否定できな
いことである。特に上記の毛髪成長期延長効果を検定
する育毛薬剤検定方法の確立は難しく、結果としてこれ
まで提供されてきた育毛剤は、毛周期の成長期へと毛髪
を誘導して育毛する上記の発毛誘導効果に着目したも
のや,の5α−レダクターゼ阻害効果に着目したもの
が多かった。However, in spite of various attempts as described above, conventional hair-growth agents have not always had sufficient hair-growth effects such as hair loss prevention and hair growth effects. This is probably because there are various causes of hair loss and the mechanism of hair growth is very complicated. The "hair-growth agents" that have been provided so far have been developed with a relatively rough concept of hair loss, in other words, the phenomenon of "hair loss", which was deliberately grasped. Is never many. The major reason for this is that it cannot be denied that the hair-growth drug assay method capable of simply assaying the hair-growth effect focusing on these mechanisms has not been sufficiently provided. In particular, it is difficult to establish a hair-growth drug assay method for assaying the above hair growth-prolonging effect, and as a result, the hair-growth agents that have been provided so far are the above-mentioned hair growth that induces hair to the growth phase of the hair cycle. Many focused on the inducing effect and on the 5α-reductase inhibitory effect.
【0004】[0004]
【発明が解決しようとする課題】そこで、本発明者はin
vitroで行う簡便な上記の毛髪成長期延長効果を検定
する育毛薬剤検定方法を確立し、その育毛薬剤検定方法
を用いて上記の毛髪成長期延長効果を有する成分を有
効成分とする育毛剤を見出すことを目指した。The object of the invention is to solve is therefore an object of the present invention have in
Establishing a simple hair-growing period assay method for assaying the above hair growth period-prolonging effect performed in vitro , and using the hair-growing period assay method to find a hair-growing agent containing the above-mentioned component having a hair growth period-prolonging effect as an active ingredient. I aimed at that.
【0005】本願は、その一連の課題のうち、特に上記
の毛髪成長期延長効果を有する成分を見出し、これを
有効成分とする育毛剤を提供することをその課題とす
る。[0005] Of the series of problems, the present application aims to find, in particular, the above-mentioned component having an effect of extending the hair growth period, and to provide a hair restorer containing this as an active ingredient.
【0006】[0006]
【課題を解決するための手段】本発明者は、種々の物質
における上記の毛髪成長期延長効果を有する成分につ
いて、本発明者が見出した育毛薬剤検定方法を用いて鋭
意検討したところ、糖グリセリドに、所望する毛髪成長
期延長効果が認められることを見出し、本発明を完成し
た。Means for Solving the Problems The present inventor diligently studied various substances having the above hair growth period-prolonging effect by using the hair-growing drug assay method found by the inventor. In addition, they found that the desired effect of extending the hair growth period was recognized, and completed the present invention.
【0007】すなわち本発明は、糖グリセリドを有効成
分として含有する育毛剤を提供する。That is, the present invention provides a hair restorer containing a sugar glyceride as an active ingredient.
【0008】この糖グリセリドは、式(I)This sugar glyceride has the formula (I)
【化2】
〔式中、R1 は糖残基であり、R2 及びR3 は、同一で
あっても互いに異なっていてもよく、水素原子、飽和脂
肪酸残基又は不飽和脂肪酸残基である。〕で表される糖
グリセリドであることが好ましい。式(I)中、飽和脂
肪酸又は不飽和脂肪酸は、式(II)
Cn Hm O2 (II)
〔式中、6≦n≦28,n+1≦m≦2n−2であ
る。〕で表される飽和脂肪酸又は不飽和脂肪酸であるこ
とが好ましい。また、式(I)中、R2 及びR3 は、水
素原子又は不飽和脂肪酸残基であることが好ましい。さ
らに、飽和脂肪酸は、シス型の不飽和脂肪酸であること
が好ましい。[Chemical 2] [In the formula, R 1 is a sugar residue, and R 2 and R 3 may be the same or different from each other and are a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue. ] It is preferable that it is a sugar glyceride represented by these. In the formula (I), the saturated fatty acid or the unsaturated fatty acid is represented by the formula (II) C n H m O 2 (II) [wherein 6 ≦ n ≦ 28 and n + 1 ≦ m ≦ 2n−2. ] It is preferable that it is a saturated fatty acid or unsaturated fatty acid represented by these. Further, in the formula (I), R 2 and R 3 are preferably hydrogen atoms or unsaturated fatty acid residues. Further, the saturated fatty acid is preferably a cis unsaturated fatty acid.
【0009】このような不飽和脂肪酸のうち特に好まし
い不飽和脂肪酸は、ペトロセリン酸,オレイン酸又はリ
ノール酸である。また、糖グリセリドにおける糖は、ガ
ラクトース,グルコース又はフルクトースであることが
好ましい。Among these unsaturated fatty acids, particularly preferred unsaturated fatty acids are petroselinic acid, oleic acid and linoleic acid. The sugar in the sugar glyceride is preferably galactose, glucose or fructose.
【0010】前記したように、本発明において「育毛
剤」は、主に後述する育毛薬剤検定方法によって少なく
とも毛包上皮系細胞の分裂増殖活性若しくは毛幹伸長活
性を維持又は促進することで毛髪の成長期を延長する効
果を有する成分を有効成分として配合した、特に上記
の毛髪成長期延長効果に着目した毛髪関連薬剤であり、
いわば「個別効能育毛剤」としての特徴を有する。[0010] As described above, in the present invention, the "hair-growth agent" means that the hair growth-promoting activity of at least the hair follicle epithelial cells is maintained or promoted by the hair-growing agent assay method described below. It is a hair-related drug containing a component having an effect of prolonging the growth period as an active ingredient, particularly focusing on the effect of prolonging the hair growth period,
So-called "individually effective hair-growth agent".
【0011】この「育毛剤」は、例えば毛根近傍におけ
る毛包上皮系細胞の増殖が緩徐であること等により成長
期が短くなって、相対的に成長期毛よりも休止期毛の割
合が多くなってしまうことに起因する脱毛症に特に有効
な薬剤である。また、他の個別効能を有する育毛剤と組
み合わせて用いることにより、幅広くの脱毛症において
は,総合的かつ相乗的な効果を上げることが可能であ
る。すなわち、この「育毛剤」は、前記した〜の効
果を包含する概念を有する一般的な育毛剤用途とは一線
を画する用途を有するものである。This "hair-growth agent" has a short growth period due to, for example, slow growth of hair follicle epithelial cells in the vicinity of hair roots, and thus has a relatively large proportion of quiescent hair rather than anagen hair. It is a particularly effective drug for alopecia caused by the fact that In addition, by using it in combination with other hair-growth agents having individual effects, it is possible to achieve a comprehensive and synergistic effect in a wide range of alopecia. That is, this "hair-growth agent" has an application that is distinct from the general use of a hair-growth agent that has the concept including the above-mentioned effects (1) to (3).
【0012】[0012]
【発明の実施の形態】以下、本発明の実施の形態につい
て説明する。本発明育毛剤は、上述したように糖グリセ
リドをその有効成分として含有する育毛剤である。BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described below. The hair restorer of the present invention is a hair restorer containing a sugar glyceride as an active ingredient thereof as described above.
【0013】本発明育毛剤の有効成分となり得る糖グリ
セリドは、人体に対する安全性が担保されている限りに
おいて特に限定されるものではないが、式(I)The sugar glyceride which can be an active ingredient of the hair-growing agent of the present invention is not particularly limited as long as the safety to the human body is ensured, but the formula (I)
【化3】
で表される糖グリセリドであることが好ましい。式
(I)中、R1 は糖残基である。この糖としては、単糖
類又は多糖類のいずれでもよく、単糖類としては、例え
ば、ガラクトース,グルコース,フルクトース,マンノ
ース等を挙げることができ、多糖類としては、ショ糖,
麦芽糖,乳糖,トレハロース,ヒアルロン酸等を挙げる
ことができる。これらの糖のうち、ガラクトース,グル
コース又はフルクトースが好ましく、ガラクトース又は
グルコースが特に好ましい。[Chemical 3] A sugar glyceride represented by In formula (I), R 1 is a sugar residue. The sugar may be either a monosaccharide or a polysaccharide. Examples of the monosaccharide include galactose, glucose, fructose, mannose, and the like, and the polysaccharide includes sucrose,
Maltose, lactose, trehalose, hyaluronic acid, etc. can be mentioned. Of these sugars, galactose, glucose or fructose are preferable, and galactose or glucose is particularly preferable.
【0014】式(I)中、R2 及びR3 は、同一であっ
ても互いに異なっていてもよく、水素原子、飽和脂肪酸
残基又は不飽和脂肪酸残基である。この飽和脂肪酸又は
不飽和脂肪酸としては、式(II)
Cn Hm O2 (II)
〔式中、6≦n≦28,n+1≦m≦2n−2であ
る。〕で表される飽和脂肪酸又は不飽和脂肪酸が好まし
い。また、式(I)中、R2 及びR3 は、水素原子又は
不飽和脂肪酸残基であることが好ましく、特に、R2 及
びR3 の少なくとも1つが、不飽和脂肪酸残基であるこ
とが好ましい。さらに、不飽和脂肪酸は、シス型の不飽
和脂肪酸であることが好ましい。In the formula (I), R 2 and R 3 may be the same or different and each is a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue. This saturated fatty acid or unsaturated fatty acid has the formula (II) C n H m O 2 (II) [wherein 6 ≦ n ≦ 28 and n + 1 ≦ m ≦ 2n−2. ] Saturated fatty acid or unsaturated fatty acid represented by Further, in the formula (I), R 2 and R 3 are preferably hydrogen atoms or unsaturated fatty acid residues, and in particular, at least one of R 2 and R 3 is an unsaturated fatty acid residue. preferable. Further, the unsaturated fatty acid is preferably a cis unsaturated fatty acid.
【0015】飽和脂肪酸としては、具体的には、例え
ば、カプロン酸,カプリル酸,カプリン酸,ラウリン
酸,ミリスチン酸,パルミチン酸,ステアリン酸,アラ
キン酸,ベヘン酸,リグノセリン酸,セロチン酸,ヘプ
タコサン酸を挙げることができ、このうち、パルミチン
酸が好ましい。Specific examples of the saturated fatty acid include caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, serotic acid, heptacosanoic acid. Among these, palmitic acid is preferable.
【0016】また、不飽和脂肪酸としては、具体的に
は、例えば、ヒドロソルビン酸,ウンデシレン酸,ドデ
セン酸,トリデセン酸,ヘプタデセン酸,ペトロセリン
酸(cis-6-オクタデセン酸),パルミトレイン酸(cis-
9-ヘキサデセン酸),オレイン酸,バクセン酸,リノー
ル酸,α−リノレン酸,γ−リノレン酸,エイコセン
酸,エイコサトリエン酸,エルカ酸(cis-13-ドコセン
酸),ドコサジエン酸,ドコサトリエン酸,ドコサテト
ラエン酸,ドコサペンタエン酸,アラキドン酸,ネルボ
ン酸(cis-15- テトラコセン酸)又はドコサヘキサエン
酸等を挙げることができる。Specific examples of unsaturated fatty acids include hydrosorbic acid, undecylenic acid, dodecenoic acid, tridecenoic acid, heptadecenoic acid, petroselinic acid (cis-6-octadecenoic acid), and palmitoleic acid (cis-
9-hexadecenoic acid), oleic acid, vaccenic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, eicosenoic acid, eicosatrienoic acid, erucic acid (cis-13-docosenoic acid), docosadienoic acid, docosatrienoic acid, Examples thereof include docosatetraenoic acid, docosapentaenoic acid, arachidonic acid, nervonic acid (cis-15-tetracosenoic acid) and docosahexaenoic acid.
【0017】これらの不飽和脂肪酸のうち、ペトロセリ
ン酸,パルミトレイン酸,オレイン酸,リノール酸,α
−リノレン酸,γ−リノレン酸,アラキドン酸及び/又
はドコサヘキサエン酸が好ましく、ペトロセリン酸,オ
レイン酸及び/又はリノール酸が特に好ましい。なお、
これらの糖グリセリドの原料が、植物、例えばコンフリ
ー等であり、このような植物から得られる糖グリセリド
(植物抽出物)を本発明育毛剤の有効成分として選択す
ることもまた好ましい。Among these unsaturated fatty acids, petroselinic acid, palmitoleic acid, oleic acid, linoleic acid, α
-Linolenic acid, γ-linolenic acid, arachidonic acid and / or docosahexaenoic acid are preferred, and petroselinic acid, oleic acid and / or linoleic acid are particularly preferred. In addition,
The source of these sugar glycerides is a plant such as comfrey, and it is also preferable to select a sugar glyceride (plant extract) obtained from such a plant as the active ingredient of the hair-growing agent of the present invention.
【0018】これらの糖グリセリドは、それぞれ通常公
知の方法で製造することができる。また、市販品を用い
ることもできるのは勿論である。これらの糖グリセリド
は、強い毛包上皮系細胞の増殖作用及び毛幹の伸長作用
を有しており、これらを単独で又は2種以上を組み合わ
せて、本発明育毛剤の有効成分とすることができる。Each of these sugar glycerides can be produced by a commonly known method. Also, it goes without saying that a commercially available product can be used. These sugar glycerides have a strong hair follicle epithelial cell proliferation action and hair shaft elongation action, and these may be used alone or in combination of two or more as an active ingredient of the hair restorer of the present invention. it can.
【0019】本発明育毛剤における上記糖グリセリドの
配合量は、本発明育毛剤の具体的形態等に応じて適宜選
択し得るものであり、特に限定されるべきものではない
が、育毛剤全体に対して1.0×10-12 〜20.0重
量%であることが好ましく、同0.01〜10.0重量
%であることが特に好ましい。The blending amount of the above-mentioned sugar glyceride in the hair restorer of the present invention can be appropriately selected according to the specific form of the hair restorer of the present invention and is not particularly limited. On the other hand, it is preferably 1.0 × 10 −12 to 20.0% by weight, and particularly preferably 0.01 to 10.0% by weight.
【0020】糖グリセリドの配合量が、育毛剤全体に対
して1.0×10-12 重量%未満では、本発明の所期の
効果である毛包上皮系細胞増殖作用に基づく毛髪成長期
延長効果が十分に発揮されず好ましくなく、同20.0
重量%を超えると、配合量の増加に見合った効果の増大
を見込めないばかりではなく、製剤上支障をきたす傾向
が顕著となり好ましくない。When the content of the sugar glyceride is less than 1.0 × 10 −12 % by weight based on the whole hair-growing agent, the desired effect of the present invention is to prolong the hair growth period based on the hair follicle epithelial cell proliferation action. The effect is not sufficiently exerted, which is not preferable.
When the content exceeds the weight%, not only the effect corresponding to the increase of the compounding amount cannot be expected, but also the tendency of causing a trouble in the formulation becomes remarkable, which is not preferable.
【0021】このようにして、上記糖グリセリドを有効
成分として配合した本発明育毛剤は、優れた毛包上皮系
細胞増殖作用に基づく毛髪成長期延長効果を有し、前記
したように、例えば毛根近傍における毛包上皮系細胞の
増殖が緩徐であること等により成長期が短くなって,相
対的に成長期毛よりも休止期毛の割合が多くなってしま
うことに起因する脱毛症に特に有効な薬剤である。ま
た、他の個別効能を有する育毛剤と組み合わせて用いる
ことにより、特定の脱毛症においては相乗的な効果を上
げることもまた可能である。In this way, the hair-growing agent of the present invention containing the above-mentioned sugar glyceride as an active ingredient has an excellent hair-growth-prolonging effect based on the excellent hair follicle epithelial cell proliferation action, and as described above, for example, hair roots. Particularly effective for alopecia due to the fact that the growth period is shortened due to slow growth of hair follicle epithelial cells in the vicinity, and the proportion of resting hair is relatively higher than that of growing hair. It is a drug. It is also possible to increase the synergistic effect in specific alopecia by using it in combination with other hair-growth agents having individual effects.
【0022】本発明育毛剤の所期の効果である毛髪成長
期延長効果における本質的作用である、毛周期における
成長期の維持又は延長作用を特定する手段は、その特定
法自体がその作用を特定するために妥当なものである限
り特に限定されず、例えばinvitroにおける特定法も,i
n vivo における特定法も用いることができるが、その
簡便性と有効性を考慮すると、in vitroにおける特定法
を用いることが好ましい。The means for identifying the effect of maintaining or extending the growth phase in the hair cycle, which is the essential effect of the desired effect of the hair-growth agent of the present invention, on the effect of extending the hair growth period, is determined by the identification method itself. is not particularly limited as far as it is reasonable to identify, also specific methods in example vitro, i
Although the in vivo identification method can be used, the in vitro identification method is preferably used in consideration of its simplicity and effectiveness.
【0023】以下、このin vitroにおける特定法の一つ
である、毛包上皮系培養細胞の増殖効果を検討すること
を特徴とする特定法について簡単に説明する(より具体
的には、実施例において記載する。)。Hereinafter, one of the in vitro identification methods, which is characterized by examining the proliferative effect of hair follicle epithelial cultured cells, will be briefly described (more specifically, Examples. In.).
【0024】すなわちこの特定法は、「毛包上皮系培養
細胞に無血清培地中で対象物質を接触させて、その細胞
の増殖活性の有無及び/又は強弱を特定することによ
り、その対象物質の毛周期における成長期を延長する効
果を検定する一次スクリーニングを行い、この一次スク
リーニングにより効果の認められた対象物質について、
この対象物質を添加した無血清培地中でヒト毛包を培養
し、毛幹の伸長が認められた対象物質をさらに選択する
二次スクリーニングを行うことを特徴とする育毛薬剤検
定方法」、すなわち毛髪の伸長に直接的に関係する毛包
上皮系細胞に着目し、この培養細胞を用いることによっ
て、所望する毛周期における成長期を延長する効果を特
定する、in vitroの育毛薬剤検定方法である。That is, this identification method is performed by "contacting a hair follicle epithelial cultured cell with a target substance in a serum-free medium and specifying the presence or absence and / or the strength of the proliferation activity of the cell, Perform a primary screening to test the effect of prolonging the growth period in the hair cycle, and for the target substance for which an effect was recognized by this primary screening,
Human hair follicles are cultured in a serum-free medium to which the target substance is added, and a secondary screening is performed to further select the target substance in which hair shaft elongation is observed. This is an in vitro method for assaying hair-growing agents, which focuses on hair follicle epithelial cells that are directly related to the elongation of hair and identifies the effect of extending the growth phase in the desired hair cycle by using these cultured cells.
【0025】この育毛薬剤検定方法の一次スクリーニン
グにおいては、においては、動物(ヒトを含む,以下同
様である)の毛包上皮系細胞を単離して得た培養細胞で
ある「毛包上皮系培養細胞」に対象物質を接触させて、
その増殖の有無及び/又は強弱を特定する。In the primary screening of this hair-growth drug assay method, in the hair-follicle epithelial cell culture obtained by isolating hair follicle epithelial cells of animals (including humans, the same applies hereinafter) Contact the target substance with the "cell",
The presence and / or strength of the proliferation is specified.
【0026】毛包上皮系細胞は、特に毛根近傍の外毛根
鞘細胞とマトリクス細胞等の毛包由来の上皮系細胞のこ
とを指し、内側の毛乳頭細胞は除外される。The hair follicle epithelial cells refer to epithelial cells derived from hair follicles, such as outer root sheath cells in the vicinity of hair roots and matrix cells, and exclude inner dermal papilla cells.
【0027】毛周期における成長期は、まさにこの毛幹
の伸長,すなわち毛包上皮系細胞が分裂して増殖してい
る時期であり、同退行期及び休止期はこれが鈍化して休
止する時期である。The growth phase in the hair cycle is just the elongation of the hair shaft, that is, the period when the hair follicle epithelial cells divide and proliferate, and the catagen period and the resting period are the periods when they become blunted and rest. is there.
【0028】つまり、毛周期における成長期を延長又は
維持する物質は、その投与により毛包上皮系細胞の分裂
及び増殖活性を維持することによって、毛髪が毛周期に
おける退行期及び休止期への移行を防ぐ物質、すなわち
毛包上皮系細胞の増殖を促進又は維持し続ける物質であ
ることが結論付けられる。That is, the substance that prolongs or maintains the growth phase in the hair cycle maintains the division and proliferative activity of hair follicle epithelial cells by its administration, whereby the hair shifts to the catagen phase and the telogen phase in the hair cycle. It is concluded that it is a substance that prevents the above, that is, a substance that continues to promote or maintain the proliferation of hair follicle epithelial cells.
【0029】また、二次スクリーニングにおいては、ヒ
ト毛包を培養し、毛幹の伸長が認められた対象物質をさ
らに選択する。この二次スクリーニングに際しては、ま
ず毛包断片を調製することが必要である。通常は、ヒト
の健毛部の頭髪の中から成長期の頭髪を選択して、この
毛髪の毛球部から約2mm上部を切断して毛包断片を調製
することができる。Further, in the secondary screening, human hair follicles are cultured, and a target substance in which hair shaft elongation is recognized is further selected. In this secondary screening, it is necessary to first prepare hair follicle fragments. Usually, hair in a growing stage is selected from the hairs of human healthy hair, and a hair follicle fragment can be prepared by cutting about 2 mm from the hair bulb of this hair.
【0030】この毛包断片は、インシュリンを含む基礎
培地で培養すれば成長期の状態が比較的長期に維持され
るが、インシュリンを含有しない基礎培地で培養すると
1週間程度の短期間のうちに退行期の毛包に類似する状
態に変化する。This hair follicle fragment is maintained in a growth phase for a relatively long period of time when cultured in a basal medium containing insulin, but when cultivated in a basal medium containing no insulin, it takes about a week or so. The condition resembles a hair follicle in the catagen period.
【0031】従って、インシュリンを含まない基礎培地
中で培養する場合は、1週間程度のうちに評価すること
が好ましく、インシュリンを含む培地を用いる場合には
2週間程度まで培養期間を延長することが可能になる。
どちらの培地においても、この毛包を対象被験物質の存
在下で培養することにより、毛幹の伸長の程度を観察す
ることができる。Therefore, when culturing in a basal medium that does not contain insulin, it is preferable to evaluate within 1 week, and when using a medium that contains insulin, the culturing period can be extended to about 2 weeks. It will be possible.
In both media, the extent of hair shaft elongation can be observed by culturing the hair follicles in the presence of the test substance of interest.
【0032】なお、この二次スクリーニングにおいて用
いる基礎培地は、一般的に用いられている動物細胞培養
用培地を用いることが可能であり、汚染防止のために抗
生物質や抗菌剤を添加することができる。As the basal medium used in this secondary screening, a commonly used medium for animal cell culture can be used, and antibiotics or antibacterial agents may be added to prevent contamination. it can.
【0033】毛包の培養条件は、5%CO2 ・37℃等
の動物培養における通常の条件で行うことができる。培
養は通常5〜14日間行われる。ヒト毛包における毛幹
の伸長は、例えばミクロメーターを装着した実体顕微鏡
において目視で確認することができる。The hair follicles can be cultured under the usual conditions for animal culture such as 5% CO 2 · 37 ° C. Culturing is usually performed for 5 to 14 days. The extension of the hair shaft in the human hair follicle can be visually confirmed by, for example, a stereoscopic microscope equipped with a micrometer.
【0034】このように上記一次スクリーニングと二次
スクリーニングとを行うことにより、毛周期における成
長期の維持又は延長作用並びに毛幹の伸長作用を特定す
ることができる。By carrying out the above-mentioned primary screening and secondary screening in this manner, it is possible to identify the action of maintaining or extending the growth phase in the hair cycle and the action of extending the hair shaft.
【0035】なお、in vitroの育毛薬剤検定方法として
は、他に対象物質を動物の毛乳頭細胞に作用させて、そ
の増殖促進効果を判定する方法も用いることができる。As an in vitro method for assaying hair-growth agents, a method in which a target substance is allowed to act on animal's hair papilla cells to determine its growth-promoting effect can also be used.
【0036】また、in vivo における特定法としては、
例えば「ヌードマウスに対象物質を投与し,このヌード
マウスの体表の発毛部位の状態を特定して,対象物質の
毛周期における成長期を延長する効果を検定する育毛薬
剤検定方法」、すなわち原則的には無毛であるが、その
体表に経時的にその発毛部位が移動する特徴的な発毛を
するヌードマウスにおける発毛部位の広さと発毛部位の
移動速度を特定することによって、毛周期における成長
期の長さを検定する方法等を挙げることができる。Further, as a specific method in vivo ,
For example, "a hair-growth drug assay method in which a target substance is administered to a nude mouse, the state of the hair growth site on the body surface of this nude mouse is specified, and the effect of the target substance to extend the growth phase in the hair cycle is assayed", In principle, it is hairless, but the hair growth site moves over time to the body surface. To identify the width of the hair growth site and the migration speed of the hair growth site in nude mice that have characteristic hair growth. The method of assaying the growth period length in the hair cycle can be mentioned.
【0037】本発明育毛剤が採り得る剤型は、外皮に適
用可能な剤型であれば特に限定されず、例えば液状,乳
液,軟膏等を選択可能である。また、本発明育毛剤の形
態は任意であり、例えばトニック,ヘアークリーム,ム
ース,シャンプー,リンス,クリーム,乳液,化粧水,
パック等の形態を採ることができる。The dosage form of the hair restorer of the present invention is not particularly limited as long as it can be applied to the outer skin, and for example, liquid, emulsion, ointment and the like can be selected. The hair restorer of the present invention may have any form, for example, tonic, hair cream, mousse, shampoo, rinse, cream, milky lotion, lotion,
It can be in the form of a pack or the like.
【0038】本発明育毛剤には、前記の必須成分に加え
て必要に応じて、かつ本発明の所期の効果を損なわない
限りにおいて、化粧品,医薬部外品,医薬品等において
一般的に用いられる各種油性若しくは水性成分,界面活
性剤,保湿剤,増粘剤,防腐剤,酸化防止剤,香料,色
材,各種薬剤等を配合することができる。In addition to the above essential ingredients, the hair restorer of the present invention is generally used in cosmetics, quasi-drugs, pharmaceuticals, etc. as needed and as long as it does not impair the intended effects of the present invention. Various oily or aqueous components, surfactants, moisturizers, thickeners, preservatives, antioxidants, fragrances, coloring materials, various chemicals and the like can be added.
【0039】例えば、高級飽和脂肪酸,固形パラフィ
ン,流動パラフィン,シリコーン油,スクワラン,モノ
オレイン酸グリセリル,オリーブ油,高級アルコール等
の油性成分;ポリオキシエチレンアルキルエーテル,ポ
リオキシエチレン硬化ヒマシ油等の界面活性剤;グリセ
リン,ヒアルロン酸,プロピレングリコール,マルチト
ール,アテロコラーゲン,乳酸ナトリウム等の保湿剤;
マルメロ粘質物,カルボキシビニルポリマー,キサンタ
ンガム等の増粘剤;サリチル酸等の防腐剤;ニコチン酸
アミド,ニコチン酸ベンジル,ビタミンEアセテート,
センブリ抽出物,塩化カルプロニウム,アセチルコリン
誘導体等の血管拡張剤;セリン,メチオニン,アルギニ
ン等のアミノ酸類;ビタミンB6 ,ビタミンE若しくは
その誘導体,ビオチン,パントテン酸若しくはその誘導
体等のビタミン類;ニコチン酸,ニコチン酸メチル,ニ
コチン酸トコフェロール等のニコチン酸エステル類;セ
ファランチン等の皮膚機能亢進剤;エストラジオール等
の女性ホルモン剤;グリチルレチン酸若しくはその誘導
体等の消炎剤;ヒノキチオール,ヘキサクロロフェン,
ベンザルコニウムクロリド,ビチオノール等の抗菌剤;
メントール等の清涼剤;亜鉛若しくはその誘導体;乳酸
若しくはそのアルキルエステル;クエン酸等の有機酸類
等を配合することができる。本発明育毛剤の具体的処方
は後述する。For example, higher saturated fatty acids, solid paraffin, liquid paraffin, oily components such as silicone oil, squalane, glyceryl monooleate, olive oil, higher alcohols; surface active agents such as polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, etc. Moisturizers such as glycerin, hyaluronic acid, propylene glycol, maltitol, atelocollagen, sodium lactate, etc .;
Quince mucilage, carboxyvinyl polymer, thickener such as xanthan gum; preservative such as salicylic acid; nicotinamide, benzyl nicotinate, vitamin E acetate,
Assemblage extract, vasodilators such as carpronium chloride and acetylcholine derivatives; amino acids such as serine, methionine and arginine; vitamins such as vitamin B 6 , vitamin E or its derivatives, biotin, pantothenic acid or its derivatives; nicotinic acid, Nicotinic acid esters such as methyl nicotinate and tocopherol nicotinate; Skin function enhancers such as cepharanthin; Female hormone agents such as estradiol; Anti-inflammatory agents such as glycyrrhetinic acid or its derivatives; Hinokitiol, hexachlorophen,
Antibacterial agents such as benzalkonium chloride and bithionol;
A cooling agent such as menthol; zinc or a derivative thereof; lactic acid or an alkyl ester thereof; organic acids such as citric acid can be blended. The specific formulation of the hair restorer of the present invention will be described later.
【0040】[0040]
【実施例】以下、実施例等により本発明をさらに具体的
に説明するが、この実施例等により本発明の技術的範囲
が限定的に解釈されるべきものではない。なお、以下の
実施例等において「%」と表示され,かつ内容量を示す
ものは、特に断らない限り重量%を意味する。まず、本
実施例等において用いた、対象物質の毛髪成長期延長作
用を評価するためのin vitroの細胞増殖試験について説
明する。EXAMPLES The present invention will be described in more detail with reference to the following examples, but the technical scope of the present invention should not be limitedly interpreted by these examples. In addition, in the following Examples and the like, "%" and the content indicates the weight% unless otherwise specified. First, an in vitro cell proliferation test for evaluating the hair growth period-prolonging effect of the target substance used in the present Examples and the like will be described.
【0041】〔試験例1〕 毛包上皮系培養細胞を用い
た細胞増殖試験
A.ヒト毛包上皮系細胞
1.ヒト毛包上皮系細胞の採取
外科手術の副産物として得られたヒト男性頭皮から毛周
期における成長期の毛包を実体顕微鏡下で機械的に採取
した。この成長期の毛包を1000 U/mL dispase・0.2 %
コラゲナーゼを含むダルベッコの改変MEM(DME
M)で30分間,37℃で処理し、注射針の先を用いて
dermal sheath やdermal papilla、毛球部上皮組織を除
去して、0.05%トリプシン・0.02%EDTAを含むリン
酸緩衝液〔PBS(−):(−)とはカルシウムイオン
やマグネシウムイオンを含まない意味である〕で5分
間,37℃で処理した。Test Example 1 Cell Proliferation Test Using Hair Follicle Epithelial Cultured Cells A. Human hair follicle epithelial cells 1. Collection of Human Hair Follicle Epithelial Cells From the human male scalp obtained as a by-product of surgery, hair follicles in the growing phase of the hair cycle were mechanically collected under a stereomicroscope. 1000 U / mL dispase ・ 0.2% of hair follicles in this growth period
Dulbecco's modified MEM containing collagenase (DME
M) for 30 minutes at 37 ° C and using the tip of a needle
Phosphate buffer solution containing 0.05% trypsin and 0.02% EDTA by removing dermal sheath, dermal papilla, and epithelial tissue of hair bulb part [PBS (−): (−) means not containing calcium ion or magnesium ion) Yes] for 5 minutes at 37 ° C.
【0042】次にコラーゲン(Type I)コーティングし
た培養皿に毛包を静置し、外殖片培養を行った。なおこ
の際の培地は、無血清培地〔Keratinocyte Growth Medi
um(KGM)〕を用いた(Keratinocyte Serum Free Me
diumを用いることもできる)。この培養の4〜5日後
に、毛包の培養皿への接着及び細胞の増殖が確認できた
時点で培地を交換し、これ以降2日おきに培地交換を行
った。Next, the hair follicles were allowed to stand on a culture dish coated with collagen (Type I), and explant culture was carried out. The medium used at this time was serum-free medium [Keratinocyte Growth Medi
um (KGM)] (Keratinocyte Serum Free Me
You can also use dium). After 4 to 5 days of this culture, the medium was exchanged when the adhesion of the hair follicles to the culture dish and the growth of cells could be confirmed, and the medium was exchanged every two days thereafter.
【0043】このようにして増殖させた細胞を、0.05wt
%トリプシン-0.02 %含有PBS(−)で37℃で5分
間処理した後、等量の0.1 %トリプシンインヒビターで
反応を停止させ、遠心処理(800×g,5 分間) を施して細
胞を回収した。The cells grown in this manner were mixed with 0.05 wt.
After treatment with PBS (-) containing 10% trypsin-0.02% for 5 minutes at 37 ° C, the reaction was stopped with an equal amount of 0.1% trypsin inhibitor, and the cells were recovered by centrifugation (800 xg, 5 minutes). .
【0044】次に、細胞を上記の無血清培地に浮遊させ
て、5000 cells/cm2の密度でコラーゲンコーティング
(Type I)した培養皿に播種し、細胞がsubconfluentに
なるまで2日おきに培地交換を行い、再び0.05wt%トリ
プシン-0.02 %EDTA含有PBS(−)で37℃で5
分間処理した後、等量の0.1 %トリプシンインヒビター
で反応を停止させ、遠心処理(800×g,5 分間) を施し
て、これにより得られたヒト毛包上皮系細胞に細胞凍結
液(セルバンカー:ダイヤトロン製)を添加し、1.0
×106 cell/mL の濃度に調整して、各凍結チューブに
1.0×106 cellずつ入れ、これを凍結保存した。な
お、これらの細胞数は、血球算定板で算出した。Next, cells were resuspended in serum-free medium described above were seeded in culture dishes collagen-coated (Type I) at a density of 5000 cells / cm 2, culture medium every two days until the cells became subconfluent Replace with PBS (-) containing 0.05wt% trypsin-0.02% EDTA again at 37 ℃.
After treatment for 1 minute, the reaction was stopped with an equal volume of 0.1% trypsin inhibitor, and the cells were centrifuged (800 × g, 5 minutes), and the resulting human hair follicle epithelial cells were frozen (cell banker). : Made by Diatron) and added 1.0
The concentration was adjusted to × 10 6 cells / mL, 1.0 × 10 6 cells were put in each freezing tube, and the frozen tubes were stored. The number of these cells was calculated using a hemocytometer.
【0045】2.対象物質のアッセイ
上記工程により得た毛包上皮系細胞の線維芽細胞混入率
(FB混入率)を測定(3000倍,5視野)し、その
結果FB混入率が3%以上のものは、アッセイの対象か
ら除外した。そして、この毛包上皮系細胞を培養フラス
コ中に播種後、これを0.25%トリプシン−0.02
%EDTA含有PBS(−)で処理した後、0.1%ト
リプシンインヒビターで反応を停止後、系を1500rp
m で5分間遠心処理を施し、上清を除去し、残渣にKG
M培地20mLを添加して、細胞懸濁液を調製した。2. Assay of target substance The fibroblast contamination rate (FB contamination rate) of hair follicle epithelial cells obtained by the above steps was measured (3000 times, 5 fields of view), and as a result, the FB contamination rate of 3% or more was assayed. Excluded from the subject. Then, the hair follicle epithelial cells were seeded in a culture flask, and then 0.25% trypsin-0.02.
After treatment with PBS (-) containing 10% EDTA, the reaction was stopped with 0.1% trypsin inhibitor, and then the system was run at 1500 rp.
Centrifuge at m for 5 minutes, remove the supernatant, and leave KG in the residue.
A cell suspension was prepared by adding 20 mL of M medium.
【0046】0.2mL/well の割合で、96well-plate
(I型コラーゲンコーティングプレート:ファルコン社
製)に播種し(3.0×103cell/well)、細胞がウエ
ルの底に沈むまで約20分間室温下で放置した。その
後、37℃,5%CO2 で1日間培養を行い、所望する
ヒト毛包上皮系培養細胞を得た。96 well-plate at a rate of 0.2 mL / well
(Type I collagen coating plate: manufactured by Falcon) (3.0 × 10 3 cells / well), and left at room temperature for about 20 minutes until the cells sink to the bottom of the well. Then, the cells were cultured at 37 ° C. and 5% CO 2 for 1 day to obtain desired human hair follicle epithelial cells.
【0047】B.ラット毛包上皮系細胞
1.ラット毛包上皮系細胞の採取:
(1)毛包の採取
新生児(3〜4日令)ラットの背部皮膚を5%PSF含
有PBS(−)に浸漬後、皮膚脂肪層から下の皮下脂肪
や皮膜等を解剖用ハサミで除去した。 次いで、再びこ
の背部皮膚を1%PSF含有PBS(−)に浸し、さら
にこれを0.25%トリプシン−0.02%EDTA含
有PBS(−)中に4℃で一晩浸した。B. Rat hair follicle epithelial cells 1. Collection of rat hair follicle epithelial cells: (1) Collection of hair follicles After immersing the dorsal skin of newborn (3-4 day old) rats in PBS (-) containing 5% PSF, The film was removed with scissors for dissection. Then, the back skin was again soaked in PBS (-) containing 1% PSF, which was further soaked in PBS (-) containing 0.25% trypsin-0.02% EDTA at 4 ° C overnight.
【0048】このトリプシン溶液中における浸漬後、背
部皮膚の真皮層と表皮層をピンセットで剥がした後、真
皮層を0.35%コラゲナーゼ含有Ham's F12培
地〔組成(mg/L):l-Alanin(8.9),l-Arginine(HCl:21
1),l-Asparagine(13.2),l-Asparatic acid(13.3),l-Cys
teine (HCl:31.5),l-Glutamic acid(14.7),l-Glutamin
e(146),Glycine(7.5),l-Histidine (HCl:19),l-Isoleu
cine(3.9),l-leucine(13.1),l-Lysine(HCl:36.5),l-Met
hionine(4.5),l-Phenylalanin(5.0),Proline(34.5),l-S
erine(10.5),l-Threonine(11.9),l-Tryptophane(2.0),l
-Tyrosine(5.4),l-Valine(11.7),Biotine(0.0073),Chol
ine(Cl:14.0),VitaminB12(1.36),葉酸(1.32),Inositol
(18.0),Nicotinamide(0.037),パントテン酸(Ca:0.477),
VitaminB6(HCl:0.062),VitaminB2(0.038),VitaminB1(HC
l:0.337),CaCl2(2H2O:44.0),CuSO4・5H2O(0.0025),FeSO
4・7H2O(0.834),KCl(224.0),MgCl2(6H2O:122),"Proc.N
atl.Acad.Sci.USA,53,288(1965)" 以下同様である〕中
で、ハサミで裁断した。この裁断物を含む培地を37℃
で35分間浸透を行った(60rpm )。浸透後、このコ
ラゲナーゼ反応物中に塊状のものが見えなくなるまでピ
ペッティングを行い、DNase (10000 unit) 含有Ha
m's F12培地を添加し、5分間放置した。After immersion in this trypsin solution, the dermis layer and epidermal layer of the back skin were peeled off with tweezers, and then the dermis layer was treated with Ham's F12 medium containing 0.35% collagenase [composition (mg / L): 1- Alanin (8.9), l-Arginine (HCl: 21
1), l-Asparagine (13.2), l-Asparatic acid (13.3), l-Cys
teine (HCl: 31.5), l-Glutamic acid (14.7), l-Glutamin
e (146), Glycine (7.5), l-Histidine (HCl: 19), l-Isoleu
cine (3.9), l-leucine (13.1), l-Lysine (HCl: 36.5), l-Met
hionine (4.5), l-Phenylalanin (5.0), Proline (34.5), lS
erine (10.5), l-Threonine (11.9), l-Tryptophane (2.0), l
-Tyrosine (5.4), l-Valine (11.7), Biotine (0.0073), Chol
ine (Cl: 14.0), Vitamin B12 (1.36), folic acid (1.32), Inositol
(18.0), Nicotinamide (0.037), Pantothenic acid (Ca: 0.477),
VitaminB6 (HCl: 0.062), VitaminB2 (0.038), VitaminB1 (HC
l: 0.337), CaCl 2 (2H 2 O: 44.0), CuSO 4・ 5H 2 O (0.0025), FeSO
4 / 7H 2 O (0.834), KCl (224.0), MgCl 2 (6H 2 O: 122), "Proc.N
atl.Acad.Sci.USA, 53,288 (1965) "and so on], and was cut with scissors. The medium containing this cut was 37 ° C.
For 35 minutes at 60 rpm. After permeation, pipetting was performed until no lumps could be seen in the collagenase reaction product, and Ha containing DNase (10000 unit).
m's F12 medium was added and left for 5 minutes.
【0049】放置後、得られた懸濁液をさらにピペッテ
ィングした後、ナイロンメッシュ(Nytex 157 mesh) で
濾過した。懸濁液をPBS(−)で希釈し、次いでこの
希釈した懸濁液に遠心処理を施した(4℃,400rpm
,5分間)。遠心後、上清を除いて脂肪分を系から除
去した。After standing, the obtained suspension was further pipetted and then filtered through a nylon mesh (Nytex 157 mesh). The suspension was diluted with PBS (-), and then the diluted suspension was centrifuged (4 ° C, 400 rpm).
, 5 minutes). After centrifugation, the supernatant was removed to remove fat from the system.
【0050】次いで、残渣にPBS(−)を添加して懸
濁後、これにさらに遠心処理を施した〔(4℃,400
rpm ,5分間)×3回〕。この遠心操作により得られた
残渣が、ラットの背部皮膚における毛包である。Next, PBS (-) was added to the residue to suspend it, and this was further centrifuged [(4 ° C., 400
rpm, 5 minutes) x 3 times]. The residue obtained by this centrifugation is hair follicles on the dorsal skin of the rat.
【0051】(2)毛包上皮系細胞の採取
上記操作により得られた毛包に、0.25%トリプシン
−0.02%EDTA含有PBS(−)を5mL添加し
て、細胞懸濁液を37℃で5分間インキュベートした。(2) Collection of hair follicle epithelial cells To the hair follicles obtained by the above operation, 5 mL of PBS (-) containing 0.25% trypsin-0.02% EDTA was added to prepare a cell suspension. Incubated at 37 ° C for 5 minutes.
【0052】インキュベート終了後、等量の0.1%ト
リプシンインヒビターとHam'sF12培地を添加し
て、細胞懸濁液をセルストレーナー(100 μm Nalgene
社製)で濾過後、この細胞懸濁液に遠心処理を施した
(4℃,1500rpm ,5分間)。この系から上清を除
去して、残渣として所望する毛包上皮系細胞を得た。こ
の毛包上皮系細胞に細胞凍結液(セルバンカー:ダイヤ
トロン製)を添加し、1.5×107 cell/mL の濃度に
調整して、各凍結チューブに1.5×107 cellずつ入
れ、これを凍結保存した。After completion of the incubation, an equal amount of 0.1% trypsin inhibitor and Ham's F12 medium were added, and the cell suspension was added to a cell strainer (100 μm Nalgene).
(Manufactured by K.K.), and the cell suspension was centrifuged (4 ° C., 1500 rpm, 5 minutes). The supernatant was removed from this system to obtain the desired hair follicle epithelial cells as a residue. The hair follicle epithelial cells in cell freezing solution (Cell Banker: Dia Tron Ltd.) was added, was adjusted to a concentration of 1.5 × 10 7 cell / mL, 1.5 × each 10 7 cell to each cryotubes It was put in and stored frozen.
【0053】2.毛包上皮系細胞の前培養:系に混入し
ている線維芽細胞を可能な限り系から除去するために、
上記工程により得られた毛包上皮系細胞の前培養を行っ
た。以下、その手順について説明する。2. Pre-culture of hair follicle epithelial cells: In order to remove as much fibroblasts contaminating the system as possible from the system,
The hair follicle epithelial cells obtained in the above step were pre-cultured. The procedure will be described below.
【0054】37℃の恒温槽で、上記工程により得た凍
結細胞を融解した。次いでFAD培地〔Ham's F1
2培地(後述)とMEN培地を容量比で3対1で混合し
たものに、インシュリン(5.0μg/mL),ハイドロコルチ
ゾン(0.45μg/mL),エピダーマルグロウスファクター
(EGF)(10.0ng/mL),コレラトキシン (10-9M)及びウシ
胎児血清(10 %) を含有させた培地、以下同様である〕
を添加し、細胞溶液を希釈して系に遠心処理を施した
(10℃以下,1500rpm ,5分間)。遠心後、上清
を除去し、系にFAD培地を添加して、細胞塊が認めら
れなくなるまでピペッティングを繰り返した。The frozen cells obtained in the above step were thawed in a 37 ° C. thermostat. Then FAD medium [Ham's F1
Insulin (5.0 μg / mL), hydrocortisone (0.45 μg / mL), epidermal growth factor were added to a mixture of 2 medium (described later) and MEN medium in a volume ratio of 3: 1.
(EGF) (10.0 ng / mL), cholera toxin (10 -9 M) and fetal calf serum (10%)-containing medium, the same shall apply hereinafter]
Was added, the cell solution was diluted, and the system was centrifuged (10 ° C. or lower, 1500 rpm, 5 minutes). After centrifugation, the supernatant was removed, FAD medium was added to the system, and pipetting was repeated until no cell mass was observed.
【0055】次いで、FAD培地で細胞濃度が2.5×
105 cell/mL になるように調整した。I型コラーゲン
でコーティングした75cm3 の培養フラスコに細胞を播
種して、これを37℃,5%CO2 で一晩培養した。培
養後、系をPBS(−)で洗浄し、0.25%トリプシ
ン−0.02%EDTA含有PBS(−)を添加して、
これを37℃,5%CO2 で4分間インキュベートし
た。次に、系にトリプシン溶液と等量の0.1%トリプ
シンインヒビターを添加して、1回軽くゆすった後で上
清を除去して、系に混入している線維芽細胞を除去し
た。Then, the cell density was 2.5 × in FAD medium.
It was adjusted to 10 5 cells / mL. The cells were seeded in a 75 cm 3 culture flask coated with type I collagen, and the cells were cultured overnight at 37 ° C. and 5% CO 2 . After culturing, the system was washed with PBS (-), 0.25% trypsin-0.02% EDTA-containing PBS (-) was added,
This was incubated for 4 minutes at 37 ° C. and 5% CO 2 . Next, 0.1% trypsin inhibitor in an amount equal to that of the trypsin solution was added to the system, the mixture was lightly shaken once, and the supernatant was removed to remove fibroblasts contaminating the system.
【0056】さらに、系にKGM培地〔表皮角化細胞基
礎培地(Keratinocyto growth medium):Keratinocyto b
asal medium (KBM培地(改変MCDB153培地
(クローネティックス社製)))に,ウシ脳下垂体エキ
ス(BPE)(0.4vol%),インシュリン(0.5μm/mL),ハイドロ
コルチゾン(0.5μm/mL),h-EGF(0.1 ng/mL)を添加した培
地、以下同様である〕を添加し、37℃,5%CO2 で
3日間培養した。Furthermore, in the system, KGM medium [Keratinocyto growth medium: Keratinocyto b
Asal medium (KBM medium (modified MCDB153 medium (manufactured by Clonetics))), bovine pituitary extract (BPE) (0.4 vol%), insulin (0.5 μm / mL), hydrocortisone (0.5 μm / mL) , h-EGF (0.1 ng / mL) -added medium, the same applies hereinafter] was added, and the cells were cultured at 37 ° C., 5% CO 2 for 3 days.
【0057】3.対象物質のアッセイ
上記工程により得た毛包上皮系細胞を播種した培養フラ
スコの線維芽細胞混入率(FB混入率)を測定(300
0倍,5視野)し、その結果FB混入率が2%以上のも
のは、アッセイの対象から除外した。3. Assay of Target Substance The fibroblast contamination rate (FB contamination rate) of the culture flask seeded with the hair follicle epithelial cells obtained in the above step was measured (300
Those with a FB contamination rate of 2% or more were excluded from the assay targets.
【0058】系をPBS(−)で洗浄し、0.25%ト
リプシン−0.02%EDTA含有PBS(−)を添加
して、これを37℃で3分間インキュベートした。次い
で上皮系細胞と線維芽細胞とのトリプシンに対する反応
性の違いを利用して,系から線維芽細胞を除去するため
に、トリプシンを除去し、再び0.25%トリプシン−
0.02%EDTA含有PBS(−)を添加して、37
℃,20rpm で5分間振盪した。The system was washed with PBS (-), PBS (-) containing 0.25% trypsin-0.02% EDTA was added, and this was incubated at 37 ° C for 3 minutes. Then, by utilizing the difference in the reactivity of epithelial cells and fibroblasts to trypsin, trypsin was removed to remove fibroblasts from the system, and 0.25% trypsin- was added again.
PBS (-) containing 0.02% EDTA was added to give 37
The mixture was shaken at 20 rpm at 5 ° C for 5 minutes.
【0059】次いで、細胞のはがれを顕微鏡下で確認し
た後、10%FBS含有DMEM培地を添加してピペッ
ティングを行い、系を1500rpm で5分間遠心処理を
施した。上清を除去し、KGM培地を添加して、細胞塊
がなくなるまでピペッティングを行った。Then, after confirming the detachment of cells under a microscope, DMEM medium containing 10% FBS was added for pipetting, and the system was centrifuged at 1500 rpm for 5 minutes. The supernatant was removed, KGM medium was added, and pipetting was performed until there were no cell clumps.
【0060】懸濁液をセルストレーナー(100 μm Nalg
ene 社製)で濾過後、懸濁液中の生細胞数を血球算定板
で算出し、系にKGM培地を添加して、系の中の細胞濃
度が2.0×104cell/mLになるように調整した。次い
で、0.2mL/well の割合で、96well-plate(I型コ
ラーゲンコーティングプレート:ファルコン社製)に播
種し(4.0×103cell/well)、細胞がウエルの底に
沈むまで約20分間室温下で放置した。その後、37
℃,5%CO2 で1日間培養を行い、所望するヒト毛包
上皮系培養細胞を得た。The suspension was added to a cell strainer (100 μm Nalg
After filtering with ene), the number of viable cells in the suspension was calculated with a hemocytometer, and KGM medium was added to the system to make the cell concentration in the system 2.0 × 10 4 cells / mL. I adjusted it so that. Then, it was seeded at a rate of 0.2 mL / well on a 96-well plate (type I collagen coating plate: manufactured by Falcon) (4.0 × 10 3 cells / well), and about 20 cells were allowed to sink to the bottom of the well. It was left at room temperature for a minute. Then 37
Culturing was carried out at 5 ° C. and 5% CO 2 for 1 day to obtain desired human hair follicle epithelial cells.
【0061】C.試験培地の調製:
(1)対象物質添加培地の調製
下記第1表に示す対象物質を培地全体に対して1.0×
10-17 〜1.0×10-4 mol/L,溶媒(DMSO)
濃度が0.1%となるように、前記KBM培地に添加し
た。C. Preparation of test medium: (1) Preparation of target substance-added medium The target substance shown in Table 1 below was 1.0 × with respect to the entire medium.
10 −17 to 1.0 × 10 −4 mol / L, solvent (DMSO)
It was added to the KBM medium so that the concentration was 0.1%.
【0062】[0062]
【表1】 [Table 1]
【0063】(2)コントロール培地の調製
・ネガティブコントロール:KBM培地に、DMSO
(溶媒)を最終濃度が0.1%となるように添加した培
地を調製した。
・ポジティブコントロール:ネガティブコントロール培
地に、最終濃度が5μg/mLのインシュリン,0.5μg/
mLのハイドロコーチゾンを添加して調製した。(2) Preparation of control medium-Negative control: KBM medium with DMSO
A medium was prepared by adding (solvent) to a final concentration of 0.1%. -Positive control: Negative control medium with a final concentration of 5 μg / mL insulin, 0.5 μg / mL
Prepared by adding mL of hydrocortisone.
【0064】D.対象物質培地交換:上記A,Bにおい
てヒト毛包上皮系培養細胞及びラット毛包上皮系培養細
胞を調製した96well-plate中のKGM培地を、対象物
質添加培地及びコントロール培地(200μl/well)と
交換して、交換後37℃,5%CO2 で2日間培養し
た。D. Exchange of target substance medium: KGM medium in 96 well-plate prepared with human hair follicle epithelial cultured cells and rat hair follicle epithelial cultured cells in the above A and B was replaced with target substance-added medium and control medium (200 μl / well) After exchange, the cells were cultured at 37 ° C. and 5% CO 2 for 2 days after the exchange.
【0065】なお、この培地の交換はウエル内のKGM
培地を,底面に付着している細胞を傷つけないように留
意しつつマルチピペットで抜いて、その後速やかに対象
物質添加培地等をウエルの両端から添加することにより
行った。The replacement of this medium was carried out by using KGM in the well.
The medium was removed with a multi-pipette, taking care not to damage the cells attached to the bottom surface, and then the target substance-containing medium and the like were immediately added from both ends of the well.
【0066】E.細胞増殖の測定:アラマーブルー(ala
mar blue:アラマーバイオサイエンス社製) を培地量
(容量)に対して、1/10量を添加して、37℃(5
%CO2 )で6時間インキュベートした。インキュベー
ト後、系の595nm及び570nmでの吸光度をマイクロ
プレートリーダー(Micro plate reader:Bio RAD社製)
を用いて測定し、下記計算式に従って細胞増殖度を算出
し、有意差検定を行った。E. Measurement of cell proliferation: alamar blue (ala
mar blue: Alamar Bioscience Co., Ltd.) was added at 1/10 volume to the volume (volume) of the medium, and the mixture was incubated at 37 ° C. (5
% CO 2 ) and incubated for 6 hours. After the incubation, the absorbance of the system at 595 nm and 570 nm was measured using a micro plate reader (Micro plate reader: manufactured by Bio RAD).
Was measured, the cell proliferation rate was calculated according to the following calculation formula, and the significant difference test was performed.
【0067】[0067]
【数1】 [Equation 1]
【0068】F.結果:測定した上記各対象物質につい
て、ネガティブコントロールに対して有意な毛包上皮系
細胞増殖促進効果が認められた濃度〔LOG〕を下記第
2表に示す。F. Results: Table 2 below shows the concentration [LOG] of each of the above-mentioned target substances in which a significant hair follicle epithelial cell growth promoting effect was observed with respect to the negative control.
【0069】[0069]
【表2】 [Table 2]
【0070】この結果より、対象物質である上記各糖グ
リセリドについて、低濃度で、毛包上皮系培養細胞の増
殖活性が確かに認められた。すなわち、上記糖グリセリ
ドには毛髪上皮系細胞の分裂増殖活性の維持による、毛
髪における成長期の維持,延長作用が認められることが
明らかになった。From these results, it was confirmed that the above-mentioned sugar glycerides, which are the target substances, had a proliferative activity on hair follicle epithelial cultured cells at a low concentration. That is, it was revealed that the above-mentioned sugar glyceride is capable of maintaining and prolonging the growth phase of hair by maintaining the mitotic proliferation activity of hair epithelial cells.
【0071】G.毛幹の伸長の検討(二次スクリーニン
グ)
さらに、下記第3表に示す対象物質について、毛髪伸長
効果を検討した。G. Examination of Hair Shaft Extension (Secondary Screening) Furthermore, the hair extension effect was examined for the target substances shown in Table 3 below.
【0072】[0072]
【表3】 [Table 3]
【0073】ヒト毛包の器官培養
実体顕微鏡下でマイクロせん刃を用いて、ヒトの頭皮か
ら成長期の毛包を単離した。単離した毛包は「Williams
E培地(Gibco)にペニシリン,ストレプトマイシ
ン及びファンギゾン(Fungizone)を加えた培地」(以
下、(−)培地ともいう)で洗浄した後に長さを測定
し、この(−)培地にさらに10ng/mL のヒドロコーチ
ゾン,10μg/mLのインスリン,10ng/mL のナトリウ
ムセレナイト及び10μg/mLのトランスフェリンを添加
した培地(以下、(+)培地ともいう)(24穴のマイ
クロプレート使用:1穴当り1mL)中に沈ませて、5%
CO2下,37℃で一晩培養した(前培養)。この前培
養後に再度培養した毛包の長さを測定して、伸長が0.
25mm以上の毛包を選択して、その伸長の程度が均等に
なるように9本ずつの3群に分けた。毛包における毛幹
の伸長は、上記のマイクロプレートをミクロメーターを
装着した倒立顕微鏡を用いて目視で観察した。 Human Hair Follicle Organ Cultures Growing hair follicles were isolated from human scalp using a microblade under a stereomicroscope. The isolated hair follicle is "Williams
E-medium (Gibco) plus penicillin, streptomycin, and fungizone (Fungizone) "(hereinafter, also referred to as (-) medium) was washed, and the length was measured, and 10 ng / mL was added to this (-) medium. In a medium containing hydrocortisone, 10 μg / mL insulin, 10 ng / mL sodium selenite and 10 μg / mL transferrin (hereinafter also referred to as (+) medium) (use of 24-well microplate: 1 mL per well) Let it sink 5%
It was cultured under CO 2 at 37 ° C. overnight (preculture). After this pre-culture, the length of the hair follicles cultured again was measured, and the elongation was 0.
Hair follicles of 25 mm or more were selected and divided into 3 groups of 9 hairs so that the degree of extension was uniform. The extension of the hair shaft in the hair follicle was visually observed using an inverted microscope equipped with the above microplate equipped with a micrometer.
【0074】対象物質の評価
対象物質である上記各糖グリセリドを最終濃度が1.0
×10-5 mol/L(DMSO0.1%)となるように、
(−)培地に対象物質のDMSO溶液を添加して調製し
た。また、同時に(−)培地に有機溶媒(DMSO)を
最終濃度が0.1%になるように添加した培地(コント
ロール培地)を調製した。 Evaluation of Target Substances Each of the above sugar glycerides, which are target substances, has a final concentration of 1.0.
× 10 -5 mol / L (DMSO 0.1%),
It was prepared by adding a DMSO solution of the target substance to the (−) medium. At the same time, a medium (control medium) was prepared by adding an organic solvent (DMSO) to the (−) medium at a final concentration of 0.1%.
【0075】前述した3つの毛包群の培地を、上記の培
地にそれぞれ交換し、さらに5日間5%CO2 下,37
℃で培養した。培養開始5日目のそれぞれの毛包の長さ
を測定し、コントロール群と対象物質添加群との毛包に
おける毛幹の伸長を比較した。その結果を第4表に示
す。The medium of the three groups of hair follicles described above was replaced with the above medium, and the medium was further incubated for 5 days under 5% CO 2 .
Cultured at ° C. The length of each hair follicle was measured 5 days after the start of culture, and the elongation of the hair shaft in the hair follicle of the control group and that of the target substance-added group were compared. The results are shown in Table 4.
【0076】[0076]
【表4】 [Table 4]
【0077】この結果より、上記糖グリセリドは、毛包
上皮系細胞の増殖を促進するのみならず、毛包における
毛幹の伸長を促進し、毛包器官において調和のとれた毛
髪成長期延長効果を有することが明らかになった。以
下、本発明育毛剤の処方を実施例として示し、さらにこ
れらの育毛効果の検討を行った。From these results, the above-mentioned sugar glyceride not only promotes the proliferation of hair follicle epithelial cells, but also promotes the elongation of the hair shaft in the hair follicle, and has a harmonious hair growth period extending effect in the hair follicle organ. It became clear to have. Hereinafter, the formulations of the hair-growing agent of the present invention are shown as examples, and the hair-growing effects thereof were examined.
【0078】〔実施例1〕 液状育毛剤の調製
リノール酸ガラクトシルグリセリド0.01%及びオレ
イン酸ガラクトシルグリセリド0.01%[Example 1] Preparation of liquid hair restorer 0.01% galactosylglyceride linoleate and 0.01% galactosylglyceride oleate
【化4】
を、70%エタノール90%、ドデシルベンゼンスルホ
ン酸0.49%、硬化ヒマシ油エチレンオキシド(40
モル)付加物0.5%及びイオン交換水(残余)と攪拌
混合して溶解させた。さらにイオン交換水(10%)を
添加混合して、液状の育毛剤を得た。この液状の育毛剤
の処方において、リノール酸ガラクトシルグリセリド及
びオレイン酸ガラクトシルグリセリドを除去して調製し
た液状の剤を比較例1として調製した。[Chemical 4] 70% ethanol 90%, dodecylbenzene sulfonic acid 0.49%, hydrogenated castor oil ethylene oxide (40%
(Mol) adduct 0.5% and ion-exchanged water (residual) with stirring to dissolve. Further, ion-exchanged water (10%) was added and mixed to obtain a liquid hair restorer. As a comparative example 1, a liquid agent prepared by removing the galactosyl glyceride of linoleic acid and the galactosyl oleic acid in the formulation of the liquid hair-growing agent was prepared.
【0079】〔実施例2〕 液状育毛剤の調製
パルミチン酸ガラクトシルグリセリド0.02%を、7
0%エタノール90%、ドデシルベンゼンスルホン酸
0.49%、硬化ヒマシ油エチレンオキシド(40モ
ル)付加物0.5%及びイオン交換水(残余)と攪拌混
合して溶解させた。さらにイオン交換水(10%)を添
加混合して、液状の育毛剤を得た。[Example 2] Preparation of liquid hair restorer 0.02% of galactosyl glyceryl palmitate was added to 7
90% of 0% ethanol, 0.49% of dodecylbenzenesulfonic acid, 0.5% of hydrogenated castor oil ethylene oxide (40 mol) adduct and ion-exchanged water (residual) were mixed with stirring to dissolve. Further, ion-exchanged water (10%) was added and mixed to obtain a liquid hair restorer.
【0080】〔実施例3〕 乳液状育毛剤の調製 以下の処方により、乳液状の育毛剤を調製した。 配合成分 配合量(重量%) (A相) リノール酸ガラクトシルグリセリド 1.0 ポリオキシエチレン(60モル)付加硬化ヒマシ油 2.0 グリセリン 10.0 ジプロピレングリコール 10.0 1,3−ブチレングリコール 5.0 ポリエチレングリコール1500 5.0 (B相) セチルイソオクタネート 10.0 スクワラン 5.0 ワセリン 2.0 プロピルパラベン 2.0 (C相) カルボキシビニルポリマー1%水溶液 30.0 ヘキサメタリン酸ソーダ 0.03 イオン交換水 8.35 (D相) イオン交換水 4.5 (E相) KOH 0.12 イオン交換水 5.0Example 3 Preparation of Emulsion Hair Growth Agent An emulsion-type hair restorer was prepared according to the following formulation. Blending ingredients Blending amount (wt%) (Phase A) Linoleic acid galactosyl glyceride 1.0 Polyoxyethylene (60 mol) addition hydrogenated castor oil 2.0 Glycerin 10.0 Dipropylene glycol 10.0 1,3-butylene glycol 5.0 Polyethylene glycol 1500 5.0 (Phase B) Cetyl isooctanoate 10.0 Squalane 5.0 Vaseline 2.0 Propylparaben 2.0 (Phase C) Carboxyvinyl polymer 1% aqueous solution 30.0 Sodium hexametaphosphate 0.03 Ion-exchanged water 8.35 (Phase D) Ion-exchanged water 4.5 (E phase) KOH 0.12 Ion-exchanged water 5.0
【0081】<製造方法>A相、B相をそれぞれ60℃
で加熱溶解し、混合してホモミキサー処理しゲルを作
り、これにD相を徐々に添加しホモミキサーで分散し
た。次にこれに溶解したC相を加え、最後に溶解したE
相を添加しホモミキサーで乳化してO/W乳液型の育毛
剤を得た。<Manufacturing Method> Phases A and B are each 60 ° C.
The mixture was heated and dissolved by heating, mixed and treated with a homomixer to form a gel, to which phase D was gradually added and dispersed with a homomixer. Next, the dissolved phase C was added to this, and finally the dissolved E
The phases were added and emulsified with a homomixer to obtain an O / W emulsion type hair restorer.
【0082】〔実施例4〕 クリーム状育毛剤の調製 以下の処方により、クリーム状の育毛剤を調製した。 配合成分 配合量(重量%) (A相) 流動パラフィン 5.0 セトステアリルアルコール 5.5 グリセリルモノステアレート 3.0 EO(20モル)−2−オクチルドデシルエーテル 8.0 プロピルパラベン 0.3 香料 0.1 (B相) リノール酸ガラクトシルグリセリド 5.0 グリセリン 8.0 ジプロピレングリコール 20.0 ポリエチレングリコール4000 5.0 ドデシル硫酸ナトリウム 0.1 ヘキサメタリン酸ソーダ 0.005 イオン交換水 39.995Example 4 Preparation of Cream Hair Growth Agent A creamy hair restorer was prepared according to the following formulation. Blending ingredients Blending amount (wt%) (Phase A) Liquid paraffin 5.0 Cetostearyl alcohol 5.5 Glyceryl monostearate 3.0 EO (20 mol) -2-octyldodecyl ether 8.0 Propylparaben 0.3 Perfume 0.1 (Phase B) Linoleic acid galactosyl glyceride 5.0 Glycerin 8.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium dodecyl sulfate 0.1 Sodium hexametaphosphate 0.005 Ion-exchanged water 39.995
【0083】<製造方法>A相、B相をそれぞれ加熱溶
解し混合し、ホモミキサーで乳化してクリーム状の育毛
剤を得た。<Production Method> Phases A and B were melted by heating, mixed, and emulsified with a homomixer to obtain a creamy hair-growing agent.
【0084】〔試験例2〕 本発明育毛剤の育毛作用の
検討
本発明育毛剤の脱毛防止、発毛効果等の育毛作用を調べ
るために、ヒトに対して、以下の方法でトリコグラム試
験を実施した。被験試料及び対照試料は、実施例1〜4
の本発明育毛剤、比較例1の剤及び70%エタノールで
ある。[Test Example 2] Examination of hair-growth action of the hair-growth agent of the present invention To examine hair-growth effects such as hair loss prevention and hair-growth effect of the hair-growth agent of the present invention, a trichogram test was conducted on humans by the following method. Carried out. The test sample and the control sample are Examples 1 to 4.
Of the present invention, the agent of Comparative Example 1 and 70% ethanol.
【0085】試験方法
上記試料の使用前と使用後の抜去毛髪の毛根を顕微鏡下
で観察し、毛根の形態から,成長の止まった毛の毛根で
ある「休止期毛根」数(脱毛を訴える人は正常な人より
もこの休止期毛根の割合が多いことが認められている)
を計数し、その割合の増減によってこれらの試料の育毛
作用を比較した。 Test method The roots of the removed hair before and after the use of the above sample were observed under a microscope, and from the morphology of the roots, the number of "resting hair roots", which were the roots of hairs that had stopped growing, Is found to have a higher proportion of this hairy root than in normal people.)
Were counted and the hair growth effect of these samples was compared by increasing or decreasing the ratio.
【0086】すなわち、被験試料及び対照試料をそれぞ
れ男性被験者10名の頭皮に1日2回,1回2mLずつ6
カ月間連続して塗布し、塗布直前及び6カ月間塗布終了
直後に被験者1名につき100本ずつ毛髪を抜去し、そ
れぞれの毛根を顕微鏡下で観察した。また、上記試料に
おける育毛効果が有効か無効かに関する実使用テストを
行った。これらの試験の結果を、下記第5表に示す。That is, the test sample and the control sample were respectively applied to the scalp of 10 male subjects twice a day, and 2 mL each time 6 mL.
The hair was continuously applied for a month, and 100 hairs were removed from each subject immediately before the application and immediately after the application for 6 months, and each hair root was observed under a microscope. In addition, a practical use test was conducted on whether the hair-growth effect in the above sample was effective or ineffective. The results of these tests are shown in Table 5 below.
【0087】[0087]
【表5】 [Table 5]
【0088】この第5表の結果から、糖グリセリドであ
るリノール酸ガラクトシルグリセリド、又は、パルミチ
ン酸ガラクトシルグリセリド、又は、リノール酸ガラク
トシルグリセリド及びオレイン酸ガラクトシルグリセリ
ドを有効成分として配合した本発明育毛剤には、これら
の糖グリセリドの毛髪成長期延長効果に基づく育毛効果
が認められることが明らかになった。また、上記の糖グ
リセリド以外の糖グリセリドについても、同様の毛髪成
長期延長効果が認められたことから、これらの糖グリセ
リドを有効成分として配合した本発明育毛剤において
も、上記の実施例と同様に育毛効果が認められることは
明らかである。From the results shown in Table 5, it is found that the hair-growing agent of the present invention containing linoleic acid galactosyl glyceride which is a sugar glyceride, palmitic acid galactosyl glyceride, or linoleic acid galactosyl glyceride and oleic acid galactosyl glyceride as active ingredients. , It was revealed that the hair-growth effect based on the hair-growth-prolonging effect of these sugar glycerides was recognized. Further, similar sugar glycerides other than the above-mentioned sugar glycerides were also found to have similar hair-growth-prolonging effects. Therefore, the hair-growing agent of the present invention containing these sugar glycerides as an active ingredient is similar to the above-mentioned examples. It is clear that the hair-growth effect is observed in.
【0089】[0089]
【発明の効果】本発明により、毛髪伸長の促進をするこ
とによって毛周期における成長期を維持又は延長する育
毛剤が提供される。Industrial Applicability According to the present invention, there is provided a hair-growing agent that maintains or extends the growth phase of the hair cycle by promoting hair growth.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 浜田 千加 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第1リサーチセンター内 (72)発明者 鈴木 順 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第1リサーチセンター内 (72)発明者 相馬 勤 神奈川県横浜市金沢区福浦2丁目12番1号 株式会社資生堂第2リサーチセンター内 (72)発明者 田島 正裕 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第1リサーチセンター内 (72)発明者 野原 稔弘 熊本県熊本市長嶺町2861−27 Fターム(参考) 4C083 AB282 AC022 AC102 AC122 AC131 AC182 AC241 AC421 AC432 AC482 AC792 AD042 AD092 AD112 AD191 AD202 CC37 DD23 DD31 EE22 ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Chika Hamada 1050 Shinba-cho, Kohoku Ward, Yokohama City, Kanagawa Prefecture Shiseido 1st Research Center (72) Inventor Jun Suzuki 1050 Shinba-cho, Kohoku Ward, Yokohama City, Kanagawa Prefecture Shiseido 1st Research Center (72) Inventor Tsutomu Soma 2-12-1, Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa Shiseido 2nd Research Center Co., Ltd. (72) Inventor Masahiro Tajima 1050 Shinba-cho, Kohoku Ward, Yokohama City, Kanagawa Prefecture Shiseido 1st Research Center (72) Inventor Toshihiro Nohara 2861-27 Nagaminecho, Kumamoto City, Kumamoto Prefecture F-term (reference) 4C083 AB282 AC022 AC102 AC122 AC122 AC131 AC182 AC241 AC421 AC432 AC482 AC792 AD042 AD092 AD112 AD191 AD202 CC37 DD23 DD31 EE22
Claims (7)
育毛剤。1. A hair restorer containing sugar glyceride as an active ingredient.
あっても互いに異なっていてもよく、水素原子、飽和脂
肪酸残基又は不飽和脂肪酸残基である。〕で表される、
請求項1記載の育毛剤。2. The sugar glyceride has the formula (I): [In the formula, R 1 is a sugar residue, and R 2 and R 3 may be the same or different from each other and are a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue. ],
The hair restorer according to claim 1.
I) Cn Hm O2 (II) 〔式中、6≦n≦28,n+1≦m≦2n−2であ
る。〕で表される、請求項2記載の育毛剤。3. The saturated or unsaturated fatty acid has the formula (I
I) C n H m O 2 (II) [wherein 6 ≦ n ≦ 28 and n + 1 ≦ m ≦ 2n−2. ] The hair restorer of Claim 2 represented by these.
又は不飽和脂肪酸残基である、請求項2又は3記載の育
毛剤。4. The hair restorer according to claim 2 or 3, wherein in the formula (I), R 2 and R 3 are hydrogen atoms or unsaturated fatty acid residues.
ある、請求項2〜4のいずれかの請求項記載の育毛剤。5. The hair restorer according to any one of claims 2 to 4, wherein the unsaturated fatty acid is a cis type unsaturated fatty acid.
イン酸及び/又はリノール酸である、請求項2〜5のい
ずれかの請求項記載の育毛剤。6. The hair restorer according to any one of claims 2 to 5, wherein the unsaturated fatty acid is petroselinic acid, oleic acid and / or linoleic acid.
ルクトースである、請求項1〜6のいずれかの請求項記
載の育毛剤。7. The hair restorer according to any one of claims 1 to 6, wherein the sugar is galactose, glucose or fructose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24777498A JP3495261B2 (en) | 1998-08-18 | 1998-08-18 | Hair restorer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24777498A JP3495261B2 (en) | 1998-08-18 | 1998-08-18 | Hair restorer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000063242A true JP2000063242A (en) | 2000-02-29 |
| JP3495261B2 JP3495261B2 (en) | 2004-02-09 |
Family
ID=17168461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24777498A Expired - Fee Related JP3495261B2 (en) | 1998-08-18 | 1998-08-18 | Hair restorer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3495261B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2869797A1 (en) * | 2004-05-10 | 2005-11-11 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON A SURFACTANT, A MONOCARBOXYLIC ACID AND A POLYOL |
| FR2886846A1 (en) * | 2005-06-10 | 2006-12-15 | Agro Ind Rech S Et Dev A R D S | Use of glycerol compounds for preparation of cosmetic composition, pharmaceutical composition for treatment of cancers not involving Epstein-Barr virus and nutritive composition |
| WO2008108001A1 (en) * | 2007-03-02 | 2008-09-12 | Toyo Shinyaku Co., Ltd. | Galactolipid |
-
1998
- 1998-08-18 JP JP24777498A patent/JP3495261B2/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2869797A1 (en) * | 2004-05-10 | 2005-11-11 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON A SURFACTANT, A MONOCARBOXYLIC ACID AND A POLYOL |
| EP1595530A1 (en) * | 2004-05-10 | 2005-11-16 | L'oreal | Cosmetic or dermatological composition containing a surfactant, a monocarboxylic acid and a polyol |
| FR2886846A1 (en) * | 2005-06-10 | 2006-12-15 | Agro Ind Rech S Et Dev A R D S | Use of glycerol compounds for preparation of cosmetic composition, pharmaceutical composition for treatment of cancers not involving Epstein-Barr virus and nutritive composition |
| EP1733731A1 (en) | 2005-06-10 | 2006-12-20 | Agro Industrie Recherches Et Developpements (A.R.D.) | New uses of Glycerol derivatives in particular in cosmetics |
| WO2008108001A1 (en) * | 2007-03-02 | 2008-09-12 | Toyo Shinyaku Co., Ltd. | Galactolipid |
| JPWO2008108001A1 (en) * | 2007-03-02 | 2010-06-10 | 株式会社東洋新薬 | Galactolipid |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3495261B2 (en) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU722427B2 (en) | Compositions and methods for stimulating hair growth | |
| JPH10265347A (en) | Agent for extending hair growth period | |
| IE913791A1 (en) | Hair growth regulating composition comprising epithelium¹cell supernatant-derived growth factor | |
| JPH10265350A (en) | Hair tonic | |
| JP4117773B2 (en) | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent | |
| JP2002097116A (en) | Cell activator | |
| US6139852A (en) | Extract composition as hair growth phase extender | |
| JP5216414B2 (en) | Hair restorer | |
| JP4789130B2 (en) | Hair restoration | |
| JP3495261B2 (en) | Hair restorer | |
| JPH1192343A (en) | Agent for prolonging hair growth period | |
| FR2753091A1 (en) | USE OF AN RXR-TYPE RETINOID RECEPTOR AGONIST TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP FALLING | |
| JP5166116B2 (en) | Hair restorer | |
| JPH10226628A (en) | Hair papilla-activating agent | |
| EP0897712A1 (en) | Cosmetic composition | |
| JP3472072B2 (en) | Hair growth extender | |
| JP2003238365A (en) | Hair grower | |
| JPH1192341A (en) | Agent for prolonging hair growth period | |
| JP2000119145A (en) | Prolongation agent for anagen hair | |
| JPH11124317A (en) | Composition for head | |
| JP2002205922A (en) | Prolongation agent for anagen of hair | |
| JPH10265348A (en) | Hair tonic | |
| JP3542700B2 (en) | Head composition | |
| JP2000095692A (en) | Hair anagen prolonging agent | |
| JPH111416A (en) | Composition for head |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20031014 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081121 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081121 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091121 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |